Filamin A in triple negative breast cancer

被引:1
|
作者
Giovannelli, Pia [1 ]
Di Donato, Marzia [1 ]
Licitra, Fabrizio [1 ]
Sabbatino, Emilia [1 ]
Tutino, Viviana [1 ]
Castoria, Gabriella [1 ]
Migliaccio, Antimo [1 ]
机构
[1] Univ Campania L Vanvitelli, Dept Precis Med, Via L De Crecchio 7, I-80138 Naples, Italy
关键词
Triple negative breast cancer; Filamin A; TNBC marker; Androgen receptor; ACTIN-BINDING PROTEIN; PERIVENTRICULAR HETEROTOPIA; ANDROGEN RECEPTOR; CROSS-LINKING; EXPRESSION; INVASION; SURVIVAL; FLNA; PHOSPHORYLATION; MIGRATION;
D O I
10.1016/j.steroids.2024.109380
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple-negative breast cancer is a rare but highly heterogeneous breast cancer subtype with a limited choice of specific treatments. Chemotherapy remains the only efficient treatment, but its side effects and the development of resistance consolidate the urgent need to discover new targets. In TNBC, filamin A expression correlates to grade and TNM stage. Accordingly, this protein could constitute a new target for this BC subtype. Even if most of the data indicates its direct involvement in cancer progression, some contrasting results underline the need to deepen the studies. To elucidate a possible function of this protein as a TNBC marker, we summarized the main characteristic of filamin A and its involvement in physiological and pathological processes such as cancer. Lastly, we scrutinized its actions in triple-negative breast cancer and highlighted the need to increase the number of studies useful to better clarify the role of this versatile protein as a marker and target in TNBC, alone or in "collaboration" with other proteins with a relevant role in this BC subgroup.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Drug Repurposing for Triple-Negative Breast Cancer
    Avalos-Moreno, Marta
    Lopez-Tejada, Araceli
    Blaya-Canovas, Jose L.
    Cara-Lupianez, Francisca E.
    Gonzalez-Gonzalez, Adrian
    Lorente, Jose A.
    Sanchez-Rovira, Pedro
    Granados-Principal, Sergio
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 34
  • [22] Recent treatment progress of triple negative breast cancer
    Yang Chang-Qing
    Liu Jie
    Zhao Shi-Qi
    Zhu Kun
    Gong Zi-Qian
    Xu Ran
    Lu Hui-Meng
    Zhou Ren-Bin
    Zhao Gang
    Yin Da-Chuan
    Zhang Chen-Yan
    PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2020, 151 : 40 - 53
  • [23] Understanding the biology of triple-negative breast cancer
    Criscitiello, C.
    Azim, H. A., Jr.
    Schouten, P. C.
    Linn, S. C.
    Sotiriou, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 13 - 18
  • [24] Targeted Treatment of Triple-Negative Breast Cancer
    Young, Joanna A.
    Tan, Antoinette R.
    CANCER JOURNAL, 2021, 27 (01) : 50 - 58
  • [25] Distant metastasis in triple-negative breast cancer
    Tseng, L. M.
    Hsu, N. C.
    Chen, S. C.
    Lu, Y. S.
    Lin, C. H.
    Chang, D. Y.
    Li, H.
    Lin, Y. C.
    Chang, H. K.
    Chao, T. C.
    Ouyang, F.
    Hou, M. F.
    NEOPLASMA, 2013, 60 (03) : 290 - 294
  • [26] The evolving management of metastatic triple negative breast cancer
    Malhotra, Monica K.
    Emens, Leisha A.
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 229 - 237
  • [27] Triple Negative Breast Cancer: Therapeutic and Prognostic Implications
    Brady-West, Doreen C.
    McGrowder, Donovan A.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (08) : 2139 - 2143
  • [28] Potential Therapeutic Targets in Triple Negative Breast Cancer
    Azim H.A.
    Azim H.A.
    Jr.
    Current Breast Cancer Reports, 2015, 7 (4) : 215 - 223
  • [29] Biological Subtypes of Triple-Negative Breast Cancer
    Hubalek, Michael
    Czech, Theresa
    Mueller, Hannes
    BREAST CARE, 2017, 12 (01) : 8 - 14
  • [30] Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
    Sharifi, Marina N.
    O'Regan, Ruth M.
    Wisinski, Kari B.
    CLINICAL BREAST CANCER, 2023, 23 (08) : 813 - 824